# Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

> **NCT00447382** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 330 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** insulin detemir
- **DRUG:** insulin aspart
- **DRUG:** insulin detemir

## Key facts

- **NCT ID:** NCT00447382
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447382, "Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00447382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*